Fertility and reproductive concerns related to the new generation of cancer drugs and the clinical implication for young individuals undergoing treatments for solid tumors
Open Access
- 11 March 2024
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 202, 114010
Abstract
No abstract availableKeywords
Funding Information
- Cancerfonden (20 0156 F)
- Cancerfonden (200170F)
This publication has 104 references indexed in Scilit:
- Pregnancy After Breast Cancer in Young BRCA CarriersJAMA, 2024
- A prospective longitudinal analysis of the predictors of amenorrhea after breast cancer chemotherapy: Impact of BRCA pathogenic variantsCancer Medicine, 2023
- Association between mutational subgroups, Warburg‐subtypes, and survival in patients with colorectal cancerCancer Medicine, 2022
- Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial)Breast Cancer Research and Treatment, 2021
- Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines†Annals of Oncology, 2020
- Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2–positive early breast cancer: Analysis from the NeoALTTO (BIG 1‐06) and ALTTO (BIG 2‐06) trialsCancer, 2018
- Thyroid dysfunctions secondary to cancer immunotherapyJournal of Endocrinological Investigation, 2017
- An Evaluation of the Impact of PD‐1 Pathway Blockade on Reproductive Safety of Therapeutic PD‐1 InhibitorsBirth Defects Research Part B: Developmental and Reproductive Toxicology, 2016
- Trastuzumab administration during pregnancy: a systematic review and meta-analysisBreast Cancer Research and Treatment, 2012
- Rapid‐onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancerCancer, 2012